Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Virbac: second quarter sales growth largely offsets the decline in the first quarter

Virbac
Posted on: 17 Jul 17

Virbac: second quarter sales growth largely offsets the decline in the first quarter

Public release - July 17, 2017


Virbac consolidated revenue in the second quarter amounted to €234.8 million, up sharply by +7.5% compared to the same period in 2016, of which organic growth was +5.7%. The main contributors to this performance were the United States, which enjoyed sustained activity over the period (+21%), aquaculture, as well as China, Brazil and Mexico. The endectocides (Sentinel) and the specialties ranges for companion animals, and the parasiticides and vaccines for bovine are growing in the quarter.

Year-to-date, first-half sales have reached €434.5 million compared to
€430.0 million in the same period of 2016, with an overall evolution of +1.1%. Excluding the favorable impact of exchange rates, sales were down slightly to -1.2%.

In the United States, activity in the first half was down -10.7%, of which -12.1% at comparable exchange rates, an improvement, however, compared with the first quarter, which was down by -44 % at constant exchange rates. Sentinel was down in ex-Virbac net sales, although ex-distributor sales remained stable over the period. Virbac sales in the Iverhart range are down sharply, although they are growing at ex-distributor sales. This increase is nevertheless much lower than anticipated and did not allow a significant restocking of the distributors given their stock level. The other ranges are stable in ex-Virbac sales, but continue to increase in sales to clinics.

Outside of the United States, the Group achieved a good first half showing a +1.1% organic growth (+3.4% at actual rates).
Europe is generally stable at constant exchange rates, notably due to a downturn in the OTC (unfavorable base effect due to the launch of Fipro Duo parasiticides in early 2016). In the rest of the world, organic growth continues to be sustained in many emerging countries, particularly in China, Brazil and Mexico. Conversely, in India, performance was strongly influenced by the double impact of demonetization at the beginning of the year and the entry into force of the new tax regulations which led distributors to massively reduce their stock at the end of June. Performance was also more contrasted in Japan due to competition. Finally, in Chile, activity decreased slightly compared to 2016 with contrasting activity (vaccines in progress and antibiotic range down, but compared to a high base in the first half of 2016).

In terms of species, sales in the companion animals segment fell overall by -4.1%, of which -4.9% at constant scope and exchange rates, reflecting a slower than expected return in the United States. Outside the United States, the decline in activity was -0.7%, of which -1.2% organic growth. The ranges most negatively impacted in comparison to the same period in 2016 are the internal and external parasiticides for companion animals and dog vaccines that have suffered from the temporary reduction of production capacity. Conversely, the specialties ranges for dogs and cats continue to progress.
Business in the food producing animal segment recorded an overall increase of +8.7%, of which +4.4% at constant rates. The positive effect of exchange rates is in Asia-Pacific and Latin America. At constant rates and perimeter, the bovine and the industrial (swine and poultry) posted healthy growth of +5.7% and +4.2% respectively. The aquaculture sector was down slightly in the first half (-0.4% at constant exchange rates).

Key figures
 

NET REVENUE
FIRST HALF 2017
Estimate
€434.5 M

_________

TOTAL GROWTH
+1.1%

_________

GROWTH AT CONSTANT EXCHANGE RATES
-1.2%

_________

GROWTH AT CONSTANT SCOPE
-1.2%

 

 

Of which :
COMPANION ANIMALS
-4.9%

 

 

FOOD PRODUCING ANIMALS
+4.4%

 

CONSOLIDATED DATA
Unaudited - in million Euros
 20172016% change Evolution
at constant exchange rates
 

Evolution at constant
scope
Net revenue - 1 st quarter 199.7211.4-5.5%-8.3%-8.3%
Net revenue - 2 nd quarter 234.8218.6+7.5%+5.7%+5.7%
Net revenue - 1 st half 434.5 430.0 +1.1% -1.2% -1.2%
Virbac: second quarter sales growth


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Virbac via GlobeNewswire
HUG#2120856
GlobeNewswire
globenewswire.com

Last updated on: 18/07/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.